GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolva Holding SA (XSWX:EVE) » Definitions » Change In Payables And Accrued Expense

Evolva Holding (XSWX:EVE) Change In Payables And Accrued Expense : CHF0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Evolva Holding Change In Payables And Accrued Expense?

Evolva Holding's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2023 was CHF0.00 Mil. It means Evolva Holding's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Jun. 2023 .

Evolva Holding's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2022 was CHF0.00 Mil. It means Evolva Holding's Accounts Payable & Accrued Expense stayed the same from Dec. 2021 to Dec. 2022 .

Evolva Holding Change In Payables And Accrued Expense Historical Data

The historical data trend for Evolva Holding's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolva Holding Change In Payables And Accrued Expense Chart

Evolva Holding Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evolva Holding Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Evolva Holding Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolva Holding Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Evolva Holding's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolva Holding (XSWX:EVE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolva Holding SA (XSWX:EVE) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
XSWX:KNRS XSWX:SPEX XSWX:ADXN XSWX:RLF OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX OCSE:GMAB ALNY BGNE BMRN SZSE:300122 RPRX
Traded in Other Exchanges
ELVAF:USA EVEz:UK
Address
Duggingerstrasse 23, Reinach, CHE, CH-4153
Website
https://www.evolva.com
Evolva Holding SA en liquidation formerly Evolva Holding SA is a biotechnology company. The company is engaged in discovering, developing, and commercializing ingredients and biomanufacturing processes for nutrition, healthcare, and wellness products. Geographically, the company operates in Switzerland and the United States where Switzerland derives a majority of its revenue.